RT Journal Article SR Electronic T1 Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 1041 OP 1049 DO 10.21873/invivo.12348 VO 35 IS 2 A1 YORIKO HASEGAWA A1 NOBUAKI MATSUBARA A1 TAKAHIRO KOGAWA A1 YOICHI NAITO A1 KENICHI HARANO A1 AKO HOSONO A1 TATSUYA ONISHI A1 TAKASHI HOJO A1 MOTOTSUGU SHIMOKAWA A1 TORU MUKOHARA YR 2021 UL http://iv.iiarjournals.org/content/35/2/1041.abstract AB Aim: Patients with triple-negative breast cancer (TNBC) who have not achieved pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) were considered for adjuvant capecitabine. This study was to explore the utility of the Neo-Bioscore in guiding post-surgical therapy in TNBC. Patients and Methods: The Neo-Bioscore was calculated for patients with non-metastatic primary breast cancer who received NAC at National Cancer Center Hospital East, Japan. Results: A total of 329 patients were evaluated. The Neo-Bioscore stratified prognosis after NAC better than clinical or pathological stage. The Neo-Bioscore performed well in the selection of patients with TNBC with excellent prognoses despite non-pCR; no death was observed in patients who had a Neo-Bioscore of 2, the lowest score in those with TNBC. Conclusion: The Neo-Bioscore can improve the prognostic stratification of patients after NAC for breast cancer over clinical and pathological staging and may enable the identification of patients with non-pCR TNBC who can avoid additional adjuvant chemotherapy.